Acaricidal activity of Melaleuca alternifolia (tea tree) oil: In vitro sensitivity of Sarcoptes scabiei var hominis to terpinen-4-ol

Archives of Dermatology

Volumn 140, Issue 5, 2004, Pages 563-566

  Walton, Shelley F ^a,b   McKinnon, Melita ^a   Pizzutto, Susan ^a   Dougall, Annette ^a   Williams, Edwina ^a   Currie, Bart J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CINEOLE; EQUIMEC; IVERMECTIN; PERMETHRIN; TEA TREE OIL; TERPINEN 4 OL; TERPINEOL;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; NONHUMAN; PRIORITY JOURNAL; SARCOPTES SCABIEI; SCABIES;

ADULT; ANIMALS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INSECTICIDES; MELALEUCA; PHYTOTHERAPY; SARCOPTES SCABIEI; SCABIES; TEA TREE OIL;

EID: 2442714101     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.5.563     Document Type: Article

References (30)

1. Arlian LG. Biology, host relations, and epidemiology of Sarcoptes scabiei. Annu Rev Entomol. 1989;34:139-161.
2. Burgess I. Sarcoptes scabiei and scabies. Adv Parasitol. 1994;33:235-292.
3. Chosidow O. Ivermectin: main results of efficacy and safety data in scabies. Paper presented at: 20th World Congress of Dermatology; July 2, 2002; Paris, France.
4. Currie BJ, Carapetis JR. Skin infections and infestations in Aboriginal communities in northern Australia. Australas J Dermatol. 2000;41:139-145.
5. Currie BJ, Connors CM, Krause VL. Scabies programs in Aboriginal communities. Med J Aust. 1994;161:636-637.
6. Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000;94:92-96.
7. Hernandez-Perez E. Resistance to antiscabietic drugs. J Am Acad Dermatol. 1983;8:121-123.
8. Coskey RJ. Scabies [letter]. Arch Dermatol. 1979;115:109.
9. Roth W. Scabies resistant to lindane 1% lotion and crotamiton 10% cream. J Am Acad Dermatol. 1991;24:502-503.
10. Yonkosky D, Ladia L, Gackenheimer L, Schultz M. Scabies in nursing homes. J Am Acad Dermatol. 1990;23:1133-1136.
11. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med. 1995;333:26-30.
12. Currie B, Huffam S, O'Brien D, Walton S. Ivermectin for scabies [letter]. Lancet. 1997;350:1551.
13. Huffam S, Currie B, Arthur A, Boustead P. Management of crusted (Norwegian) scabies. Aust Infect Control. 1997;2:13-20.
14. Walton SJ, McBroom J, Mathews JD, Kemp DJ, Currie BJ. Crusted scabies. Clin Infect Dis. 1999;29:1226-1230.
15. Budhiraja SS, Cullum ME, Sioutis SS, Evangelista L, Habanova ST. Biological activity of Melaleuca alternifolia (Tea Tree) oil component, terpinen-4-ol, in human myelocytic cell line HL-60. J Manipulative Physiol Ther. 1999;22:447-453.
16. Carson C, Riley T. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol. 1995;78:264-269.
17. Raman A, Weir U, Bloomfield SF. Antimicrobial effects of tea-tree oil and its major components on Staphylococcus aureus, Staph. epidermidis and Propionibacterium acnes. Lett Appl. Microbiol. 1995;21:242-245.
18. Cox SD, Mann CM, Markham JL. Interactions between components of the essential oil of Melaleuca alternifolia. J Appl Microbiol. 2001;91:492-497.
19. Brimer L, Bonlokke L, Pontoppidan C, Henriksen SA, Gyrd-Hansen N, Rasmussen F. A method for in vitro determination of the acaricidal effect of ivermectin using Sarcoptes scabiei var. suis as test organism. Vet Parasitol. 1995;59:249-255.
20. Burgess IF, Brown CM, Peock S, Kaufman J. Head lice resistant to pyrethroid insecticides in Britain [letter]. BMJ. 1995;311:752.
21. Mumcuoglu K, Hemingway J, Miller J, et al. Permethrin resistance in the head louse Pediculus capitis from Israel. Med Vet Entomol. 1995;9:427-432.
22. Downs AM, Stafford KA, Hunt LP, Ravenscroft JC, Coles GC. Widespread insecticide resistance in head lice to the over-the-counter pediculicides in England, and the emergence of carbaryl resistance. Br J Dermatol. 2002;146:88-93.
23. Ernst E, Huntley A. Tea tree oil: a systematic review of randomized clinical trials. Forsch Komplementarmed Klass Naturheilkd. 2000;7:17-20.
24. Banes-Marshall L, Cawley P, Phillips CA. In vitro activity of Metateuca afternifolia (tea tree) oil against bacterial and Candida spp. isolates from clinical specimens. Br J Biomed Sci. 2001;58:139-145.
25. Satchell AC, Saurajen A, Bell C, Barnetson RS. Treatment of interdigital tinea pedis with 25% and 50% tea tree oil solution: a randomized, placebo-controlled, blinded study. Australas J Dermatol. 2002;43:175-178.
26. Carson CF, Ashton L, Dry L, Smith DW, Riley TV. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. J Antimicrob Chemother. 2001;48:450-451.
27. Caelli M, Porteous J, Carson CF, Heller R, Riley TV. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2000;46:236-237.
28. Carson CF, Riley TV. Safety, efficacy and provenance of tea tree (Metateuca alternifolia) oil. Contact Dermatitis. 2001;45:65-67.
29. Hart PH, Brand C, Carson CF, Riley TV, Prager RH, Finlay-Jones JJ. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res. 2000;49:619-626.
30. Brand C, Ferrante A, Prager RH, et al. The water-soluble components of the essential oil of Metaleuca alternifolia (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro. Inflamm Res. 2001;50:213-219.